Literature DB >> 12907442

Molecular histogenesis of posttransplantation lymphoproliferative disorders.

Daniela Capello1, Michaela Cerri, Giuliana Muti, Eva Berra, Pierluigi Oreste, Clara Deambrogi, Davide Rossi, Giampietro Dotti, Annarita Conconi, Mario Viganò, Umberto Magrini, Giovanbattista Ippoliti, Enrica Morra, Annunziata Gloghini, Alessandro Rambaldi, Marco Paulli, Antonino Carbone, Gianluca Gaidano.   

Abstract

Posttransplantation lymphoproliferative disorders (PTLDs) represent a serious complication of solid organ transplantation. This study assessed the molecular histogenesis of 52 B-cell monoclonal PTLDs, including 12 polymorphic PTLDs (P-PTLDs), 36 diffuse large B-cell lymphomas (DLBCLs), and 4 Burkitt/Burkitt-like lymphomas (BL/BLLs). Somatic hypermutation (SHM) of immunoglobulin variable (IgV) genes documented that most monoclonal B-cell PTLDs (75% P-PTLDs, 91.3% DLBCLs, 100% BL/BLLs) derive from germinal center (GC)-experienced B cells. B-cell lymphoma 6 (BCL6) mutations occurred in 25% P-PTLDs, 60.6% DLBCLs, and 75.0% BL/BLLs. A first histogenetic category of PTLDs (31.2% DLBCLs) express the BCL6+/multiple myeloma oncogene-1 protein (MUM1-/+)/CD138- profile and mimic B cells experiencing the GC reaction, as also suggested by ongoing SHM in a fraction of these cases. A second subset of PTLDs (66.7% P-PTLDs and 31.2% DLBCLs) display the BCL6-/MUM1+/CD138- phenotype and mimic B cells that have concluded the GC reaction. A third histogenetic category of PTLDs (25.0% P-PTLDs and 31.2% DLBCLs) shows the BCL6-/MUM1+/CD138+ profile, consistent with preterminally differentiated post-GC B cells. Crippling mutations of IgV heavy chain (IgVH) and/or IgV light chain (IgVL) genes, leading to sterile rearrangements and normally preventing cell survival, occur in 4 DLBCLs and 1 BL/BLL that may have been rescued from apoptosis through expression of Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1). Overall, the histogenetic diversity of monoclonal B-cell PTLDs may help define biologically homogeneous categories of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907442     DOI: 10.1182/blood-2003-05-1683

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection.

Authors:  Biplab Bose; Subrata Sinha
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

3.  Hepatic involvement by lymphoproliferative disorders post liver transplantation: PTLD.Int. Survey.

Authors:  Morteza Izadi; Mozhgan Fazel; Seyed Hasan Saadat; Saeed Taheri
Journal:  Hepatol Int       Date:  2011-03-30       Impact factor: 6.047

4.  Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Authors:  Baochun Zhang; Sven Kracker; Tomoharu Yasuda; Stefano Casola; Matthew Vanneman; Cornelia Hömig-Hölzel; Zhe Wang; Emmanuel Derudder; Shuang Li; Tirtha Chakraborty; Shane E Cotter; Shohei Koyama; Treeve Currie; Gordon J Freeman; Jeffery L Kutok; Scott J Rodig; Glenn Dranoff; Klaus Rajewsky
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

Review 5.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

Review 6.  Epstein Barr virus-associated tumours: an update for the attention of the working pathologist.

Authors:  H-J Delecluse; R Feederle; B O'Sullivan; P Taniere
Journal:  J Clin Pathol       Date:  2007-09-14       Impact factor: 3.411

7.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

Authors:  Monica Messina; Ilaria Del Giudice; Hossein Khiabanian; Davide Rossi; Sabina Chiaretti; Silvia Rasi; Valeria Spina; Antony B Holmes; Marilisa Marinelli; Giulia Fabbri; Alfonso Piciocchi; Francesca R Mauro; Anna Guarini; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Robin Foà
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

8.  IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.

Authors:  Loránd L Kis; Daniel Salamon; Emma K Persson; Noémi Nagy; Ferenc A Scheeren; Hergen Spits; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Genome wide DNA-profiling of HIV-related B-cell lymphomas.

Authors:  Daniela Capello; Marta Scandurra; Giulia Poretti; Paola M V Rancoita; Michael Mian; Annunziata Gloghini; Clara Deambrogi; Maurizio Martini; Davide Rossi; Timothy C Greiner; Wing C Chan; Maurilio Ponzoni; Santiago M Moreno; Miguel A Piris; Vincenzo Canzonieri; Michele Spina; Umberto Tirelli; Giorgio Inghirami; Andrea Rinaldi; Emanuele Zucca; Riccardo D Favera; Franco Cavalli; Luigi Maria Larocca; Ivo Kwee; Antonino Carbone; Gianluca Gaidano; Francesco Bertoni
Journal:  Br J Haematol       Date:  2009-10-12       Impact factor: 6.998

10.  EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.

Authors:  Elizabeth L Courville; Sophia Yohe; David Chou; Valentina Nardi; Aleksandr Lazaryan; Beenu Thakral; Andrew C Nelson; Judith A Ferry; Aliyah R Sohani
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.